Do analysts rate ARTL or WINT?

Artelo Biosciences presently has a consensus target price of $54.00, indicating a potential upside of 4,764.86%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Artelo Biosciences is more favorable than Windtree Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Windtree Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, ARTL or WINT?

Artelo Biosciences is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A Windtree Therapeutics N/A N/A -$1.79M -$8.77 N/A

Is ARTL or WINT more profitable?

Windtree Therapeutics' return on equity of -207.34% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -1,600.12% -224.62% Windtree Therapeutics N/A -207.34% -50.19%

Do analysts prefer WINT or CASI?

CASI Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Windtree Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Windtree Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer QLGN or WINT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qualigen Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Windtree Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, QLGN or WINT?

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Qualigen Therapeutics N/A N/A -$6.26M -$7.50 N/A Windtree Therapeutics N/A N/A -$1.79M -$8.77 N/A

Is QLGN or WINT more profitable?

Qualigen Therapeutics' return on equity of 0.00% beat Windtree Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Qualigen Therapeutics N/A N/A -202.16% Windtree Therapeutics N/A -207.34% -50.19%

Do analysts prefer WINT or SHPH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Windtree Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Shuttle Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, WINT or SHPH?

Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Windtree Therapeutics N/A N/A -$1.79M -$8.77 N/A Shuttle Pharmaceuticals N/A N/A -$11.72M -$47.70 N/A

Is WINT or SHPH more profitable?

Windtree Therapeutics' return on equity of -207.34% beat Shuttle Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Windtree Therapeutics N/A -207.34% -50.19% Shuttle Pharmaceuticals N/A -408.34% -138.15%

Windtree Therapeutics (WINT) Competitors

$0.02 0.00 (0.00%)

As of 07/2/2026 03:58 PM Eastern

Compare

WINT vs. ARTL, ORGS, CASI, QLGN, and SHPH

Should you buy Windtree Therapeutics stock or one of its competitors? MarketBeat compares Windtree Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Windtree Therapeutics include Artelo Biosciences (ARTL), Orgenesis (ORGS), CASI Pharmaceuticals (CASI), Qualigen Therapeutics (QLGN), and Shuttle Pharmaceuticals (SHPH). These companies are all part of the "pharmaceutical products" industry.

How does Windtree Therapeutics compare to Artelo Biosciences?

Artelo Biosciences (NASDAQ:ARTL) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Windtree Therapeutics' return on equity of -207.34% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-1,600.12%	-224.62%
Windtree Therapeutics	N/A	-207.34%	-50.19%

Artelo Biosciences has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 3.2% of Artelo Biosciences shares are owned by company insiders. Comparatively, 0.2% of Windtree Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Artelo Biosciences is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A
Windtree Therapeutics	N/A	N/A	-$1.79M	-$8.77	N/A

In the previous week, Artelo Biosciences had 6 more articles in the media than Windtree Therapeutics. MarketBeat recorded 6 mentions for Artelo Biosciences and 0 mentions for Windtree Therapeutics. Artelo Biosciences' average media sentiment score of 0.83 beat Windtree Therapeutics' score of 0.00 indicating that Artelo Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Artelo Biosciences	Positive
Windtree Therapeutics	Neutral

Artelo Biosciences presently has a consensus target price of $54.00, indicating a potential upside of 4,764.86%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Artelo Biosciences is more favorable than Windtree Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Windtree Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Windtree Therapeutics beats Artelo Biosciences on 7 of the 12 factors compared between the two stocks.

How does Windtree Therapeutics compare to Orgenesis?

Windtree Therapeutics (NASDAQ:WINT) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

In the previous week, Windtree Therapeutics' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
Windtree Therapeutics	Neutral
Orgenesis	Neutral

29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 0.2% of Windtree Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Windtree Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Windtree Therapeutics	N/A	-207.34%	-50.19%
Orgenesis	-3,827.81%	N/A	-130.18%

Windtree Therapeutics has higher earnings, but lower revenue than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Windtree Therapeutics	N/A	N/A	-$1.79M	-$8.77	N/A
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A

Windtree Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market. Comparatively, Orgenesis has a beta of 2.89, suggesting that its stock price is 189% more volatile than the broader market.

Summary

Windtree Therapeutics beats Orgenesis on 6 of the 10 factors compared between the two stocks.

How does Windtree Therapeutics compare to CASI Pharmaceuticals?

Windtree Therapeutics (NASDAQ:WINT) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

In the previous week, Windtree Therapeutics' average media sentiment score of 0.00 equaled CASI Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Windtree Therapeutics	Neutral
CASI Pharmaceuticals	Neutral

29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Windtree Therapeutics has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Windtree Therapeutics	N/A	-207.34%	-50.19%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

Windtree Therapeutics has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market.

CASI Pharmaceuticals has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Windtree Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Windtree Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Windtree Therapeutics has higher earnings, but lower revenue than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Windtree Therapeutics	N/A	N/A	-$1.79M	-$8.77	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

Summary

CASI Pharmaceuticals beats Windtree Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Windtree Therapeutics compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:QLGN) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

In the previous week, Qualigen Therapeutics' average media sentiment score of 0.00 equaled Windtree Therapeutics'average media sentiment score.

Company	Overall Sentiment
Qualigen Therapeutics	Neutral
Windtree Therapeutics	Neutral

Qualigen Therapeutics has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Windtree Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Windtree Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A
Windtree Therapeutics	N/A	N/A	-$1.79M	-$8.77	N/A

Qualigen Therapeutics' return on equity of 0.00% beat Windtree Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qualigen Therapeutics	N/A	N/A	-202.16%
Windtree Therapeutics	N/A	-207.34%	-50.19%

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are owned by institutional investors. 1.8% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 0.2% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Windtree Therapeutics beats Qualigen Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Windtree Therapeutics compare to Shuttle Pharmaceuticals?

Windtree Therapeutics (NASDAQ:WINT) and Shuttle Pharmaceuticals (NASDAQ:SHPH) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Shuttle Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Windtree Therapeutics	N/A	N/A	-$1.79M	-$8.77	N/A
Shuttle Pharmaceuticals	N/A	N/A	-$11.72M	-$47.70	N/A

Windtree Therapeutics' return on equity of -207.34% beat Shuttle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Windtree Therapeutics	N/A	-207.34%	-50.19%
Shuttle Pharmaceuticals	N/A	-408.34%	-138.15%

Windtree Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market. Comparatively, Shuttle Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market.

29.3% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 4.6% of Shuttle Pharmaceuticals shares are held by institutional investors. 0.2% of Windtree Therapeutics shares are held by insiders. Comparatively, 12.6% of Shuttle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Windtree Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Shuttle Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Shuttle Pharmaceuticals had 6 more articles in the media than Windtree Therapeutics. MarketBeat recorded 6 mentions for Shuttle Pharmaceuticals and 0 mentions for Windtree Therapeutics. Shuttle Pharmaceuticals' average media sentiment score of 1.31 beat Windtree Therapeutics' score of 0.00 indicating that Shuttle Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Windtree Therapeutics	Neutral
Shuttle Pharmaceuticals	Positive

Summary

Windtree Therapeutics beats Shuttle Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

Get Windtree Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

WINT vs. The Competition

Export

Metric	Windtree Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$720K	$3.76B	$7.17B	$12.46B
Dividend Yield	N/A	2.16%	2.67%	6.49%
P/E Ratio	0.00	21.43	27.75	24.70
Price / Sales	N/A	324.82	533.82	98.65
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.02	8.66	10.96	6.46
Net Income	-$1.79M	$23.81M	$3.57B	$337.01M
7 Day Performance	N/A	3.39%	2.11%	1.70%
1 Month Performance	N/A	6.15%	2.79%	0.68%
1 Year Performance	N/A	62.61%	33.39%	23.94%

Windtree Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
WINT Windtree Therapeutics	N/A	$0.02 flat	N/A	-98.2%	$720K	N/A	N/A	30	Gap Down
ARTL Artelo Biosciences	2.2276 of 5 stars	$1.26 +2.4%	$54.00 +4,185.7%	-96.6%	$2.87M	N/A	N/A	5	Short Interest Decrease
ORGS Orgenesis	N/A	$0.50 -4.8%	N/A	-69.9%	$2.56M	$662K	N/A	150	Gap Down
CASI CASI Pharmaceuticals	N/A	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180
QLGN Qualigen Therapeutics	N/A	$1.36 -6.8%	N/A	-66.2%	$2.31M	N/A	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:WINT) was last updated on 7/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Windtree Therapeutics (WINT) Competitors

WINT vs. ARTL, ORGS, CASI, QLGN, and SHPH

How does Windtree Therapeutics compare to Artelo Biosciences?

Summary

How does Windtree Therapeutics compare to Orgenesis?

Summary

How does Windtree Therapeutics compare to CASI Pharmaceuticals?

Summary

How does Windtree Therapeutics compare to Qualigen Therapeutics?

Summary

How does Windtree Therapeutics compare to Shuttle Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WINT vs. The Competition

Windtree Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Windtree Therapeutics (WINT) Competitors

WINT vs. ARTL, ORGS, CASI, QLGN, and SHPH

How does Windtree Therapeutics compare to Artelo Biosciences?

Is ARTL or WINT more profitable?

Which has more risk and volatility, ARTL or WINT?

Do institutionals & insiders believe in ARTL or WINT?

Which has higher earnings & valuation, ARTL or WINT?

Does the media refer more to ARTL or WINT?

Do analysts rate ARTL or WINT?

Summary

How does Windtree Therapeutics compare to Orgenesis?

Does the media refer more to WINT or ORGS?

Do institutionals and insiders hold more shares of WINT or ORGS?

Is WINT or ORGS more profitable?

Which has better earnings & valuation, WINT or ORGS?

Which has more risk & volatility, WINT or ORGS?

Summary

How does Windtree Therapeutics compare to CASI Pharmaceuticals?

Does the media prefer WINT or CASI?

Do institutionals and insiders have more ownership in WINT or CASI?

Is WINT or CASI more profitable?

Which has more volatility & risk, WINT or CASI?

Do analysts prefer WINT or CASI?

Which has stronger earnings & valuation, WINT or CASI?

Summary

How does Windtree Therapeutics compare to Qualigen Therapeutics?

Does the media refer more to QLGN or WINT?

Which has more risk & volatility, QLGN or WINT?

Do analysts prefer QLGN or WINT?

Which has stronger valuation & earnings, QLGN or WINT?

Is QLGN or WINT more profitable?

Do insiders & institutionals believe in QLGN or WINT?

Summary

How does Windtree Therapeutics compare to Shuttle Pharmaceuticals?

Which has higher valuation & earnings, WINT or SHPH?

Is WINT or SHPH more profitable?

Which has more risk and volatility, WINT or SHPH?

Do institutionals & insiders hold more shares of WINT or SHPH?

Do analysts prefer WINT or SHPH?

Does the media refer more to WINT or SHPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

WINT vs. The Competition

Windtree Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools